|
|
News Breaks
|
October 27, 2009
|
| 08:00 EDT |  | BAYRY |
| theflyonthewall.com: | Bayer Q3 CropScience sales down 8.7% | | Sales of Bayer CropScience declined in Q3 against the strong level of the prior-year period. Sales were down by 8.7% “The market environment for Bayer CropScience was marred by lower prices for key crop commodities, adverse weather conditions and higher trade inventories of crop protection products,” said Management Board Chairman Werner Wenning. Sales growth in Latin America was not sufficient to offset a considerable drop in business in Europe and North America. :theflyonthewall.com |
|
|
News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 16:09 EDT | | BAYRY |
| theflyonthewall.com: | Watson Pharmaceuticals confirms Beyaz patent challenge | | Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug FDA seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg. Watson's ANDA product is a generic version of Bayer HealthCare Pharmaceuticals' (BAYRY) Beyaz. Beyaz is an oral contraceptive indicated for use by women to prevent pregnancy, treat symptoms of premenstrual dysphoric disorder for women who choose to use an oral contraceptive for contraception, treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control, and raise folate levels in women who choose to use an oral contraceptive for contraception. :theflyonthewall.com |
| | 15:30 EDT |  | BAYRY |
| | 14:11 EDT | | BAYRY |
| | 11:58 EDT |  | BAYRY |
|
|
January 30, 2012
|
| 07:29 EDT | | BAYRY |
| theflyonthewall.com: | The FDA Pediatric Advisory Committee to hold a meeting | | The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information